Didier Cussac

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

Mark J. Millan, Alain P. Gobert, F. Lejeune et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 509 citations · Full text

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

Mark J. Millan, Lisa Maiofiss, Didier Cussac et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 477 citations · Full text

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

Agnès L. Auclair, J.-C. Martel, M.B. Assié et al. · Neuropharmacology · 2013 · 259 citations · Full text

Psychotropic Medication, Psychopharmacology, Pharmacotherapy +17

Ras, Rap, and Rac Small GTP-binding Proteins Are Targets for Clostridium sordellii Lethal Toxin Glucosylation

Michel R. Popoff, Esteban Chaves‐Olarte, Emmanuel Lemichez et al. · Journal of Biological Chemistry · 1996 · 207 citations · Full text

Glycobiology, Immunology, Proteomics +18

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes

Adrian Newman‐Tancredi, Didier Cussac, Yann Quentric et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 192 citations